intrinsic value may be hidden?I too hold a fair chunk and am long ekg.v...Products are one thing and the people behind them are another..The crew at this company were getting stale.Its great to see some reputable additions to the bod over the past 6 months.This shakeup was overdue...
Sure the tshirts and bracelets are all great but i believe the best news release latelly did not recieve its justice .If they can implement their products with success at Servier Canada at 120 clinics simultaneously this could set the stage for proven rollout.Pharma could be a game changer.Having a great product and the ability to roll it out in a timely matter sets this company up for success. This is the pilot for large scale.This is the true test of their complete package..I have posted below part of old news release and one that was not affiliated with cardiocomm.I post this not to influence but rather for consideration and to give my take on the companies future prospects.As with any investment due diligence is paramount.
The three year program entitled "TEMPO" involves the loan of HeartCheck™ ECG monitors to approximately 120 cardiology clinics active in treating heart failure patients across Canada. The specific objective of TEMPO is to facilitate the taking of diagnostic-level, in-office ECG readings at busy practices to help improve the treatment of heart failure patients across the country. The TEMPO program will be supported in compliance with the Innovative Medicines Code of Ethical Practices.The opportunity to support the pharmaceutical sector is a logical progression for CardioComm, as ECG monitoring is a critical element in clinical studies for the evaluation of new medications, as well as for launch and post-launch of approved medications that have cardio protective effects. CardioComm's technologies hold a unique market advantage for being compliant to HIPAA standards and ECG device agnostic. TORONTO, April 3, 2017 /CNW Telbec/ - Servier Canada, the Canadian subsidiary of Servier, the second largest French pharmaceutical company, has just opened its new offices in Toronto. "Establishing a strong footprint in downtown Torontois part of our continued commitment to invest in Canada. Key to our success is fostering further collaborations with the Ontario innovative life sciences ecosystem, particularly in the Greater Toronto Area," stated Frederic Fasano, Chief Executive Officer of Servier Canada.
"Toronto has a century-long track record of outstanding health innovations and discoveries, and we continue to offer world-class academic institutions, premiere research facilities and diversity of talent that attracts businesses, like Servier Canada, to invest, grow and succeed here" said Ella Korets-Smith, Executive Director of TO Health!, one of the founding organizations of THIW.
Through investments and partnerships with small biotech companies, research institutions and Ontario Universities, Servier Canada is a key contributor to the life sciences and research in Ontario. The new Toronto Office reaffirms and deepens that commitment.
Despite significant advances, cardiovascular health remains an area with unmet medical needs and is a key priority for Servier. To improve disease understanding and patient management, Servier launched the largest international cardiovascular registry – CLARIFY in 45 countries, including Canada. This real world evidence project, conducted by the Applied Health Research Centre, part of St. Michael's Hospital in Toronto, followed more than 33,000 patients worldwide, including 1200 Canadian patients for five years to improve disease management by identifying gaps between clinical evidence and actual practice. Furthermore, the Medical and Research Sciences Discovery District (MaRS) based research project "Developing Novel Therapeutic Targets for Heart Failure" is a partnership between the Servier Research Group and the University of Ottawa Heart Institute centred on discovering and developing potential novel targets for heart failure therapy. With Servier funding of $500,000 and matching funding from the Canadian Institute of Health Research, this investment will further the understanding, treatment and prevention of heart disease in Canada.
Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters in Suresnes (France). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21 000 people worldwide. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Being completely independent, the Group reinvests 25% of turnover in research and development and uses all its profits for growth.